Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 7, 2004, Pages 744-749

  Ziegenhagen, Dieter J ^a   Kruis, Wolfgang ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Evangelisches Krankenhaus Kalk   (Germany)

Author keywords

Cisapride; Constipation; Irritable bowel syndrome; Randomized trial

Indexed keywords

CISAPRIDE; LAXATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 3242767685     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03384.x     Document Type: Article

References (18)

1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 998-1005.
2. Wells NEJ, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment. Pharmacol. Ther. 1997; 11: 1019-30.
3. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N. Engl. J. Med. 2001; 344: 1846-50.
4. Passaretti S, Titobello A, Capozzi C, Verlinden M. Cisapride accelerates total intestinal transit in patients with irritable bowel syndrome associated constipation. Progr. Med. 1987; 43 (Suppl. 1): 121-9.
5. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. 'Prokinetic' treatment of constipation-predominant irritable bowel syndrome. A placebo-controlled study of cisapride. J. Clin. Gastroenterol. 1991; 13: 49-57.
6. Schütze K, Brandstätter G, Dragosics B, Judmaier G, Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment. Pharmacol Ther. 1997; 11: 387-94.
7. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde Ø, Trondstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand. J. Gastroenterol. 1998; 33: 128-31.
8. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazacca G. Functional bowel disease and functional abdominal pain. Gastroenterol. Int. 1992; 5: 75-91.
9. Altman DG, Gardner MJ. Calculating confidence intervals for means and their differences. In: Gardner MJ, Altman DE, eds. Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1990; 20-7.
10. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232-41.
11. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 1994; 8: 499-510.
12. Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 (Suppl. II): II69-II77.
13. Talley NJ, Nyren O, Drossman DA et al. The irritable bowel syndrome: Toward optimal design of controlled treatment trials. Gastroenterol. Int. 1993; 6: 189-211.
14. Evans PR, Bak YT, Kellow JE. Effects of oral cisapride on small bowel motility in irritable bowel syndrome. Aliment. Pharmacol Ther. 1997; 11: 837-44.
15. Akehurst R, Kalthenthaler E. Treatment of irritable bowel syndrome: a review of randomized controlled trials. Gut 2001; 48: 272-82.
16. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2001; 15: 355-61.
17. Talley NJ. Serotonergic neuroenteric modulators. Lancet 2001; 358: 2061-8.
18. Kruis W, Thieme CH, Weinzierl M, Schüssler P, Holl J, Paulus W. A diagnostic score for the irritable bowel syndrome. Gastroenterology 1984; 87: 1-7.